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Strengths and limitations of this study
 ► This innovative cross-disciplinary study will com-
bine qualitative, microbiological and epidemiological 
methodologies to investigate drivers of antimicrobial 
resistance (AMR) in rural China.
 ► It will systematically document key drivers of, and 
patient pathways leading to, antibiotic use and es-
tablish the feasibility of microbiological testing and 
epidemiological monitoring for AMR and antibiotic 
use at frontline medical settings in rural China.
 ► The mixed methods approach will provide a com-
prehensive picture of factors influencing prescribing 
and sampling practices so that bias arising from 
any individual dataset can be accounted for in the 
analysis and interpretation of results strengthened 
through triangulation.
 ► The study area, though selected to be representa-
tive of rural populations in China, only includes three 
rural counties of 105 counties in Anhui province. As 
such, results may have limited generalisability.
 ► Nonetheless, the study will identify modifiable in-
fluences on current treatment-seeking pathways 
leading to antibiotic use and determine the feasibil-
ity of measuring and monitoring AMR in rural popu-
lations; these findings will inform efforts to reduce 
inappropriate prescribing and improve antimicrobial 
stewardship.
AbStrACt
Introduction This study aims to investigate patterns 
of antibiotic treatment-seeking, describe current levels 
of and drivers for antibiotic use for common infections 
(respiratory tract and urinary tract infections) and test the 
feasibility of determining the prevalence and epidemiology 
of antimicrobial resistance (AMR) in rural areas of Anhui 
province, in order to identify potential interventions to 
promote antibiotic stewardship and reduce the burden of 
AMR in China.
Methods and analysis We will conduct direct 
observations, structured and semistructured interviews 
in retail pharmacies, village clinics and township health 
centres to investigate treatment-seeking and antibiotic 
use. Clinical isolates from 1550 sputum, throat swab 
and urine samples taken from consenting patients at 
village and township health centres will be analysed 
to identify bacterial pathogens and ascertain antibiotic 
susceptibilities. Healthcare records will be surveyed for a 
subsample of those recruited to the study to assess their 
completeness and accuracy.
Ethics and dissemination The full research protocol 
has been reviewed and approved by the Biomedical 
Ethics Committee of Anhui Medical University (reference 
number: 20170271). Participation of patients and doctors 
is voluntary and written informed consent is sought 
from all participants. Findings from the study will be 
disseminated through academic routes including peer-
reviewed publications and conference presentations, via 
tailored research summaries for health professionals, 
health service managers and policymakers and through 
an end of project impact workshop with local and regional 
stakeholders to identify key messages and priorities for 
action.
IntroduCtIon
The problem of drug-resistant infections is 
widely acknowledged to be of global public 
health concern, with non-essential use of anti-
biotics in humans a major contributor.1 There 
is substantial evidence that antibiotics are over-
used in the Chinese healthcare system.2–8 A 
range of possible reasons for unnecessary use 
of antibiotics have been identified, including 
‘demand side’ issues such as cultural expec-
tations and social norms leading patients to 
expect antibiotic treatment and ‘supply side’ 
issues such as perverse financial incentives for 
prescribing antibiotics, systemic pressures on 
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which lead to overprescribing as a risk-reduction strategy. 
Of these, service providers may play a dominant role.
Health professionals in the UK and China often claim 
that antibiotic overuse is driven by patient demand and 
link this, in turn, to lack of public understanding of anti-
biotic effectiveness and low public awareness.9 Studies in 
both the UK and China suggest, however, that ‘patient 
demand’ may actually be a misperception on the part of 
healthcare providers or a rationalisation of their own anti-
biotic prescribing practices.10–13 A study of self-medica-
tion in Hefei City, Anhui province, found an association 
between higher maternal education, medical insurance 
cover and non-prescribed use of antibiotics for chil-
dren’s illnesses.14 A UK study of prescribing in primary 
care showed doctors’ perceptions of patient pressure to 
be a consistently stronger predictor of prescribing than 
patients’ actual preferences.15 On the other hand, it is 
not uncommon for doctors in both the UK and China 
to prescribe antibiotics ‘just in case’, due to a desire to 
reduce medical, legal and reputational risk in the face of 
clinical uncertainty.16 17
A cluster-randomised survey was conducted during the 
development of this protocol and 2600 rural residents in 
12 counties of Anhui province were asked about self-re-
ported health service-seeking and antibiotic consump-
tion.18 Almost three quarters (72.7%) of respondents 
reported that they would do as told if their doctors let 
them leave an appointment without prescribing any 
medicine and only 14.3% had ever asked their doctors 
to prescribe specific drugs.19 Results also suggested that 
knowledge about antibiotics (which pathogens they can 
be used to treat and what the potential risks are of using 
them) was associated with increased purchasing of over-
the-counter pharmaceuticals and with reuse of leftover 
pharmaceuticals from family or friends.
There is evidence from China that health systems, 
especially remuneration mechanisms, may be important 
drivers of unnecessary antibiotic use.20 Patients are used 
to paying only for medicines they are given and medi-
cine forms an important source of revenue for all care 
providers. Historically, remuneration mechanisms have 
provided a perverse financial incentive for healthcare 
practitioners to overprescribe antibiotics, particularly at 
lower levels of the health system.21 Recent government 
healthcare reforms, together with policies such as the 
Special Antimicrobial Use Rectification programme, have 
been associated with reductions in antibiotic prescribing 
at county and higher level public hospitals.3 However, 
current policies aim to reduce overall use (eg, by capping 
the overall proportion of antibiotic prescriptions at 
hospitals), but do not necessarily ensure equitable access 
to essential treatment; restricting overall availability of 
antibiotics may exacerbate health inequities through its 
negative effects on access to effective treatment among 
the poor.22
Current policies and interventions mainly focus on anti-
biotic prescribing, but in many settings, non-prescribed 
antibiotics are widely consumed. In China, antibiotics are 
freely available over-the-counter without prescription, 
but little is known for either urban or rural settings about 
what prompts people to seek treatment at different health 
facilities or the role of the informal sector (including 
self-medication, retail pharmacies, traditional Chinese 
medicine practitioners, unqualified biomedicine practi-
tioners and home care) in the management of infections.
Microbiological facilities are not available at most 
frontline healthcare settings. Most research on antimi-
crobial resistance (AMR) in China has, therefore, drawn 
on patient data collected in urban teaching hospitals. 
Because patients can choose to attend facilities at any level 
of the three-tier health system (community clinics, town-
ship health centres or county-level hospitals) and care 
pathways do not follow a predictable pattern of upwards 
referral, the extent to which antibiotic prescribing in 
urban hospitals drives the spread of antibiotic resis-
tance in the wider population is currently unknown. 
The often asserted high burden of AMR in China may 
be misleading since current assumptions are based on 
potential pathogens isolated in selected microbiology 
laboratories enrolled in the national surveillance system 
and it is uncertain if this reflects the incidence of resis-
tance in non-hospitalised patients with mild to moderate 
infection receiving antibiotics, most of whom do not have 
samples sent to the laboratory.23 24 UK data indicates that 
1:35 patients presenting to their General Practitioners 
(GPs) with acute cough have microbiological sampling 
and perhaps 1:5 with urinary tract infection (UTI).25 This 
data indicates that resistance rates to key antibiotics based 
on biased laboratory data may be over-emphasised.26 27
There is a need for comprehensive and systematic 
assessment of prescribing and purchasing practices in 
the context of China’s unique health systems and poli-
cies, to identify potential targets for interventions to opti-
mise prescribing and consumption. There are also crucial 
gaps in evidence regarding antibiotic resistance and its 
determinants in rural communities and health facilities 
at village and township levels in China and it is important 
to investigate the possibility of introducing routine moni-
toring of prevalence and epidemiology of AMR in these 
settings.
Study aims and objectives
This study aims to investigate levels of antibiotic prescribing 
and the burden of AMR in rural areas in China and iden-
tify key drivers of antibiotic use for common infections 
in the community, in order to identify potential interven-
tions to promote antibiotic stewardship and reduce the 
burden of AMR.
The study objectives are summarised in (Box 1).
MEthodS And AnAlySIS
Study design
This is a mixed-method study comprising two main 
components: a microbiological feasibility study and clin-
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box 1 Study objectives
1. Assess feasibility of obtaining community-based samples, isolating 
common pathogens and determining their antibiotic susceptibilities 
for presentations of Urinary Tract Infections (UTIs) and Respiratory 
Tract Infections (RTIs)
2. Estimate prevalence of AMR in non-hospitalised patients and test 
the hypothesis that community prevalence of AMR is lower than that 
based on analyses of samples from large urban hospitals with a 
higher proportion of inpatients
3. Describe patient clinical record systems and assess the reliability of 
information from electronic patient records for monitoring antimi-
crobial usage and AMR
4. Analyse microbiological findings in relation to patient-reported 
symptoms,clinical diagnoses and antibiotics prescribed in clinical 
facilities;
5. Investigate what types and sources of health care rural residents of 
Anhui Province seek for common respiratory tract infections from 
all forms andsources of health care (including informal, Traditional 
Chinese Medicine)
6. Understand what drives antibiotic provision (both prescribed and 
purchased without prescription) and consumption for selected con-
ditions at lower levelsof the formal (government-run facilities) and 
informal (retail pharmacies and any other treatment sources) health 
care system; and
7. Assess what types ofand targets for intervention are likely to be 
most effective for optimizing antibiotic use.
of antimicrobial prescribing and purchasing practices 
(objectives 5–7).
Setting
This study is being implemented in three rural residen-
tial areas in Anhui province, including one village clinic, 
one township health centre and all local retail pharma-
cies (4–8) within each area. One of the three areas will 
be used to pilot the study. Anhui province is located in 
northeast China and has a population of 68.6 million of 
whom 57% live in rural areas. Per capita GDP and income 
in Anhui rank in the middle (14th) among all provinces 
in the nation. Its social, cultural and economic back-
ground is representative of over 80% of the population 
in China. There are 968 hospitals, 1941 community and 
1398 township health centres and 15 288 village clinics in 
the province (Annual Health Anhui Statistics 2014). As in 
most other provinces, there is no strict referral system in 
Anhui and patients may choose from any level and kind 
of caregiver, though medical insurance systems enact a 
10%–20% decreasing reimbursement ratio for direct 
medical expenditures incurred at primary care settings 
upward. In terms of first time medical care, 62.9% is 
at village or community clinics, 17.3% at township or 
community health centres and 13.6% at county level 
hospitals (Annual Anhui Health Statistics 2014).
Participants
The microbiological substudy aims to recruit a total 
of 1550 patients (1000 with exacerbation of chronic 
obstructive pulmonary disease (COPD) and 555 with 
UTI). We estimate that this will yield 200 Escherichia coli 
isolates and 100 Streptococcus pneumoniae isolates, which 
should provide sufficient power to allow us to estimate key 
antibiotic susceptibilities (objective 4), on the assumption 
that:
 ► 40% of UTI samples will yield a pathogen.
 ► 25% of COPD samples will yield a pathogen.
 ► 90% of pathogens isolated from urine will be E. coli.
 ► 40% of pathogens isolated from sputum will be S. 
pneumoniae.
 ► In E. coli, resistance to nitrofurantoin, fosfomycin and 
co-amoxiclav will be <5% and resistance to cephalo-
sporins and fluoroquinolones 50%–60%.28
 ► In S. pneumoniae, penicillin resistance will be 12.5% 
and erythromycin resistance 90%.29
Inclusion criteria of patients are male or female who 
are: (1) 18 years or older and able to give consent to 
participate in the microbiological study, exit survey and/
or follow-up interviews; (2) presenting to the recruitment 
site for his/her current illness for the first time during the 
study period and (3) diagnosed by the attending doctor 
as having one or more of the following: UTI, exacerba-
tion of COPD, upper respiratory tract infection (RTI) 
with productive cough and sore throat. These patients 
will be selected via ‘consecutive sampling’ in which, 
when a start date has been determined, the recruitment 
continues daily (7 days a week) thereafter, between 08:00 
and 17:00 hours or 09:00 and 18:00 hours on alternate 
days, until the target numbers have been reached. All 
incoming patients to the site village clinics and township 
health centres who meet the inclusion criteria during any 
study day are invited to participate. This is a pragmatic 
approach to sampling since patient record systems do not 
allow the flexibility to carry out random sampling, and 
ongoing recruitment will ensure the most efficient use of 
staff and resources in this setting.
Qualitative study participants will include: (1) patients 
visiting the selected village clinics and township health 
centres during the study period; (2) customers visiting 
the selected retail pharmacies during the study period; 
(3) doctors within the clinics or health centres for treat-
ment of RTIs/UTIs; (4) salespersons working within the 
selected retail pharmacies.
data collection
Specimen collection and microbiological testing (objectives 1, 2 
and 4)
The study will collect sputum, throat swab and urine 
specimens for pathogen identification and suscep-
tibility testing. Sputum will be collected from RTI 
patients with productive cough (eg, exacerbation of 
COPD; throat swabs from patients with sore throat 
and urine from patients with UTIs. Specimen collec-
tion will be performed by the attending doctor and 
placed into a sterilised tube according to a standard 
operation protocol. The specimen tubes will be put 
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–4℃ temporarily prior to being shipped to the Central 
Laboratory of Anhui Medical University (AMU). At 
about 12:00 and 17:30 hours each day, the samples in 
the refrigerator will be transferred to a portable code 
case filled with ice bags which is then sealed and handed 
over to a contracted bus company. The company is held 
responsible for shipping the specimens within a set time 
limit (within 4 hours).
On arrival of any batch of specimens at AMU central 
lab, a designated technician will perform standard spec-
imen assessment and pretreatment and then bacteria 
inoculation, identification and susceptibility tests. 
Sputum and throat swab specimens will be inoculated 
on four plates (a blood agar plate, a MacConkey agar 
plate, a chocolate agar plate and a chrome agar plate); 
and urine specimens inoculated on two plates (a blood 
agar plate and a MacConkey agar plate). The inoculated 
blood agar and chocolate agar plates will be cultured 
and incubated in an atmosphere of 5% CO2 at 35°C; the 
MacConkey agar and the chrome agar plates, incubated 
in air at 35°C. The incubation time will be 18–24 hours 
plus an additional 24 hours if no bacteria are observed 
for the first period. Bacteria identification will use auto-
mated methods, that is, the MicroscanWalkaway-96 
System with PC33 (for gram-positive bacteria) or NC50 
(for gram-negative bacteria) kits and also according to 
different biochemical reactions as follows: (1) E. coli 
chrome agar/VITEK2 or MALDI-TOF; (2) S. pneumo-
niae optochin/biochemistry; (3) Haemophilus influenzae 
X+V factors or MALDI-TOF and (4) Moraxella catarrhalis 
MALDI-TOF. For the bacteria susceptibilities, automated 
methods will be used (VITEK2 and MicroScan Walk 
Away 96 plus) along with disk diffusion and agar dilu-
tion methods (according to CLSI). Multidrug resistance 
will be defined according to standard criteria as set out 
by Magiorakos et al.30Antimicrobial susceptibility data 
on the key pathogens identified in community sampling 
will be extracted from the existing diagnostic laboratory 
databases for comparison with isolates from village clinics 
and county hospitals. A timeline for data collection can 
be found in online supplementary appendix table 1; a 
full list of bacterial isolates and susceptibility testing can 
be found in online supplementary appendix table 2.
Electronic record review (objectives 3 and 4)
Medical record-keeping systems in Anhui province will 
be described in detail using information from clinic 
observations and consultations with clinical personnel 
and medical centre directors. Outpatient electronic 
care systems will be interrogated 2 weeks or more after 
patient recruitment and compared with notes from clinic 
observations to assess completeness and accuracy of elec-
tronic care records. A 1-year sample of all electronic care 
records from the participating facilities will then be drawn 
to investigate patterns and rates of antibiotic prescribing 
in relation to recorded diagnosis, clinical indication and 
laboratory results.
Structured exit surveys (objectives 5 and 6)
Exit surveys will be carried out with patients presenting 
with symptoms of sore throat, RTI or UTI following either 
their consultation at a healthcare facility or their visit to a 
retail pharmacy. Those who consent to being recruited will 
complete the survey prior to leaving the facility. Using a 
brief semistructured questionnaire developed from open-
ended interview responses in the study’s pilot phase, the 
survey will solicit details of symptoms, perception of the 
problem (lay diagnosis), professional and/or self-treat-
ment taken before the visit, whether the diagnosis and 
treatment received (including prescribed antibiotics) is 
as expected, as well as views on specimen collection and 
microbiological testing in patients attending the health-
care facility.
Semistructured observations (objectives 3, 5 and 6)
These will occur at all the participating clinics, health 
centres and retail pharmacies. At clinics and health 
centres, the observation focuses on daily operational 
routine including test ordering, prescribing, patient 
recall and other standard procedures using a prede-
signed worksheet, together with observational notes on 
clinical encounters. At retail pharmacies, the observation 
uses a similar worksheet and documents daily encoun-
ters between customers and shop assistants including the 
health problems presented, and medicines and informa-
tion asked for by the customers and/or suggestions made 
and medicines and information given by the assistants.
In-depth interviews (objectives 5 and 6)
These will involve a subsample of the patients (previous 
experience of similar studies suggests that around 60 in 
total are likely to be needed to reach data saturation) 
and customers (around 60) who have completed the 
exit survey and all the related doctors and salespersons 
who have served the participating patients or costumers. 
Interviews with individual patients and customers will be 
undertaken, respectively, at their homes and at the phar-
macy 1–2 weeks after their initial visit; interviews with indi-
vidual doctors and salespersons will take place any time 
during the study period when they are free. Topic guides 
refined during the pilot phase of the study will be used to 
focus patient interviews on the illness episode for which 
treatment was sought and any previous action taken to 
manage the illness, while interviews with doctors focus 
on the following main topics: professional experience 
and expertise, normal practice, prescribing antibiotics, 
patient influences on antibiotic prescribing and external 
influences on antibiotic prescribing.
A subsample of interviewees will take part in pile sorts, 
a qualitative method in which informants are provided 
with a set of index cards each showing a pertinent term 
and asked to group the cards according to their perceived 
appropriate clustering of terms. Terms will be antibiot-
ics-related and derived from earlier exit surveys, observa-
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another means to distinguish how informants understand 
antibiotics and their use.
data analysis
Quantitative analysis (objectives 1–4)
Data from the microbiological testing, review of clinical 
records and exit surveys will be analysed quantitatively 
to investigate prevalence of infection and rates of resis-
tance, relationships between infection/resistance rates 
and patient characteristics and feasibility of routine 
microbiological testing in rural clinics. The feasibility of 
obtaining community-based samples of common patho-
gens and determining their antibiotic sensitivities (objec-
tive 1) will be examined by: (1) ratios of patients who 
have provided specimens versus those who have refused 
and their reasons for doing so; (2) percentages of spec-
imens assessed as being properly collected, preserved 
and shipped by designated microbiological technicians; 
(3) ratios of positive versus negative attitudes toward 
giving specimens among the exit interviewees and views 
of the participating doctors. Prevalence of pathogens 
and AMR (objective 2) will be assessed by: (1) estimating 
percentages of pathogen positive specimens in terms of 
all and specific bacteria by diagnosis, type of specimen, 
patient-reported symptoms, previous treatment history 
and sociodemographics; (2) calculating percentages of 
resistant pathogens by type of bacteria and antibiotics 
and (3) comparing, using χ² test, these pathogen and 
resistance rates in non-hospitalised patients with those 
from analyses of data from large urban hospitals. We will 
produce a descriptive analysis of patient record systems 
and electronic record completeness and accuracy (objec-
tive 3). If sample sizes allow it, descriptive analyses may 
be followed by analytical studies to explore relationships 
between pathogen types and susceptibilities and patient 
characteristics such as presenting symptoms, clinical diag-
nosis, prior use of antibiotics and demographics (objec-
tive 4).
Qualitative analysis (objectives 5–7)
Analysis of the qualitative data (in-depth interviews, 
observations) will focus on identifying characteristic 
patterns in treatment-seeking pathways to antibiotic use 
among patients and antibiotic purchasers (objective 5) 
and on identifying key social, cultural, health systems and 
behavioural determinants of both antibiotic prescribing 
and provision among healthcare providers and of anti-
biotic use among residents (objective 6). Thematic 
and framework analysis will be undertaken for each of 
the four qualitative datasets using a similar approach. 
Following translation of a subset of interviews from 
each data set, members of the research team will inde-
pendently free code a minimum of three interview tran-
scripts in Mandarin or English and then meet to compare 
and finalise a code list. Further interviews will be coded 
thematically in batches in the software package NVivo 12 
using the agreed codes until all data have been coded. 
Each interviewer will also summarise each interview 
transcript by entering a summary of the coded data in a 
Framework using Excel. Pile sorts will be analysed using 
Johnson's Hierarchical Cluster analysis, providing a 
two-dimensional concept mapping of the terms that are 
most frequently grouped together.
The occurrence of resulting themes will also be used 
to produce theme frequency maps and theme networks 
via NVivo or UCINET for different groups of participants 
and different topics.
Analysis of antibiotics-related pathways comprises iden-
tifying both a complete set of paths for common RTIs/
UTIs and factors affecting patient trajectories among 
these pathways. Anticipated path sets to be produced 
include a general path set applicable for both RTIs and 
UTIs and an RTI and UTI-specific path set, respectively. 
Similarly, factor sets of interest in this study comprise 
combinations of factors that affect selection between: (1) 
doing nothing versus taking action; (2) self-care versus 
professional treatment; (3) western medicine versus tradi-
tional Chinese medicine; (4) antibiotics versus non-anti-
biotics therapy.
Analytic synthesis
Development of interventions for optimising antibiotics 
use (objective 7) will build on findings from both quan-
titative and qualitative analyses. It will also analyse the 
pathways and determinants identified from this study in 
relation to the Behaviour Change Wheel, a theoretical 
framework developed from 19 frameworks of behaviour 
change identified in a systematic literature review.33 The 
COM-B (‘capability’, ‘opportunity’, ‘motivation’ and 
‘behaviour’) model, which recognises behaviour as part 
of an interacting system, will be used to identify key modi-
fiable influences leading to the use of antibiotics and 
subsequently, inform recommendations for interventions 
to optimise antibiotic use.
Patient and public involvement
Development of the research question was informed by 
patients’ experiences and preferences as documented 
in a previous study.19 The results will be disseminated to 
study participants and other stakeholders through a local 
dissemination workshop to be held at the end of this 
study and through short summaries of research findings.
EthICS And dISSEMInAtIon
This protocol is rooted in a multidisciplinary collabora-
tion between institutions in the UK and China. Investiga-
tors will benefit from exchange of academic knowledge 
and methodologies and will gain situational awareness 
which extends beyond their own area of expertise. This 
will lead to greater depth of insight into the scope and 
interrelatedness of influencing factors and allow the team 
to analyse and interpret study results with full awareness 
of the complexity of drivers of AMR and antibiotic use in 
rural Anhui province. The research will provide academics 
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scale research involving a multidisciplinary team across 
two countries, as well as a ‘worked example’ of research 
capacity-building through academic collaboration for the 
benefit of a middle-income country. Regular workshops 
will allow the China and UK research teams to exchange 
ideas and insights throughout the duration of the study. 
Lessons from this study will be shared with the wider 
academic community through peer-reviewed publica-
tions and conference presentations.
This innovative study will provide the first systematic 
documentation of routes and means to antibiotic use by 
residents at lower ends of the healthcare system (town-
ship and village clinics) in China and assess the feasibility 
of routine microbiological testing and analysis of antimi-
crobial sensitivities in the context of information from 
clinic healthcare records.
Findings from the study will be summarised for the 
benefit of public health policymakers, health profes-
sionals and health service managers in China and else-
where. A final workshop will be held for the purpose 
of presenting the evidence generated by this study and 
working with local and regional stakeholders to translate 
this evidence into public health action.
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